晚期实体瘤-话题@MedSci

#晚期实体瘤#

42篇内容 | 2420人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1443148, encodeId=5dd7144314844, content=<a href='/topic/show?id=feee598219f' target=_blank style='color:#2F92EE;'>#晚期实体瘤#</a>, objectTitle=如何治疗间皮素阳性晚期实体瘤？新型T细胞疗法TC-210有效性显著, objectType=article, longId=198174, objectId=d7451981e47c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d7451981e47c, replyNumber=0, likeNumber=122, createdTime=2020-07-29, rootId=0, userName=446798725_87912766, userId=55065029738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d7451981e47c, moduleTitle=如何治疗间皮素阳性晚期实体瘤？新型T细胞疗法TC-210有效性显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d7451981e47c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1443147, encodeId=d2bb144314ea4, content=<a href='/topic/show?id=feee598219f' target=_blank style='color:#2F92EE;'>#晚期实体瘤#</a>, objectTitle=ATG-008联合特瑞普利单抗完成首例晚期实体瘤和HCC患者给药, objectType=article, longId=193347, objectId=3a3319334ea1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a3319334ea1, replyNumber=0, likeNumber=102, createdTime=2020-05-03, rootId=0, userName=446798725_87912766, userId=55065029738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a3319334ea1, moduleTitle=ATG-008联合特瑞普利单抗完成首例晚期实体瘤和HCC患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a3319334ea1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1443146, encodeId=78881443146d9, content=<a href='/topic/show?id=feee598219f' target=_blank style='color:#2F92EE;'>#晚期实体瘤#</a>, objectTitle=AACR 2020：索凡替尼联合特瑞普利单抗治疗晚期实体瘤Ⅰ期研究结果公布, objectType=article, longId=193342, objectId=4e5d193342f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e5d193342f4, replyNumber=0, likeNumber=70, createdTime=2020-05-03, rootId=0, userName=446798725_87912766, userId=55065029738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e5d193342f4, moduleTitle=AACR 2020：索凡替尼联合特瑞普利单抗治疗晚期实体瘤Ⅰ期研究结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e5d193342f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1443145, encodeId=b18d144314515, content=<a href='/topic/show?id=feee598219f' target=_blank style='color:#2F92EE;'>#晚期实体瘤#</a>, objectTitle=Lancet Oncol：Larotrectinib治疗TRK融合阳性晚期实体瘤, objectType=article, longId=189095, objectId=34b1189095d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34b1189095d4, replyNumber=0, likeNumber=59, createdTime=2020-03-03, rootId=0, userName=446798725_87912766, userId=55065029738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34b1189095d4, moduleTitle=Lancet Oncol：Larotrectinib治疗TRK融合阳性晚期实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34b1189095d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1443144, encodeId=49d71443144d7, content=<a href='/topic/show?id=feee598219f' target=_blank style='color:#2F92EE;'>#晚期实体瘤#</a>, objectTitle=Hyleukin-7（NT-I7）联合Pembrolizumab治疗复发难治晚期实体瘤：美国FDA已批准IND申请, objectType=article, longId=186916, objectId=68271869169f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68271869169f, replyNumber=0, likeNumber=99, createdTime=2020-01-30, rootId=0, userName=446798725_87912766, userId=55065029738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68271869169f, moduleTitle=Hyleukin-7（NT-I7）联合Pembrolizumab治疗复发难治晚期实体瘤：美国FDA已批准IND申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68271869169f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1443143, encodeId=5b9f144314390, content=<a href='/topic/show?id=feee598219f' target=_blank style='color:#2F92EE;'>#晚期实体瘤#</a>, objectTitle=加拿大卫生部批准VITRAKVI®（larotrectinib）治疗NTRK基因融合的晚期实体瘤, objectType=article, longId=176548, objectId=f7e11e654865, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f7e11e654865, replyNumber=0, likeNumber=77, createdTime=2019-08-01, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f7e11e654865, moduleTitle=加拿大卫生部批准VITRAKVI®（larotrectinib）治疗NTRK基因融合的晚期实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f7e11e654865)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1443142, encodeId=ff601443142ab, content=<a href='/topic/show?id=feee598219f' target=_blank style='color:#2F92EE;'>#晚期实体瘤#</a>, objectTitle=ASCO2019 |新型融合抗PD-L1抗体试用在中国晚期实体瘤患者中的应用, objectType=article, longId=167544, objectId=773f16e5442b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=773f16e5442b, replyNumber=0, likeNumber=89, createdTime=2019-06-04, rootId=0, userName=446798725_87912766, userId=55065029738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=773f16e5442b, moduleTitle=ASCO2019 |新型融合抗PD-L1抗体试用在中国晚期实体瘤患者中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=773f16e5442b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1443141, encodeId=582e1443141e9, content=<a href='/topic/show?id=feee598219f' target=_blank style='color:#2F92EE;'>#晚期实体瘤#</a>, objectTitle=SYNB1891与PD-L1检查点抑制剂联合治疗晚期实体瘤, objectType=article, longId=166726, objectId=d16c166e26ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d16c166e26ac, replyNumber=0, likeNumber=62, createdTime=2019-05-25, rootId=0, userName=446798725_87912766, userId=55065029738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d16c166e26ac, moduleTitle=SYNB1891与PD-L1检查点抑制剂联合治疗晚期实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d16c166e26ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1443140, encodeId=5e42144314042, content=<a href='/topic/show?id=feee598219f' target=_blank style='color:#2F92EE;'>#晚期实体瘤#</a>, objectTitle=OSE Immunotherapeutics的免疫检查点抑制剂： SIRPα单抗BI 765063获批在晚期实体瘤患者中进行1期临床研究, objectType=article, longId=161788, objectId=2b6a161e88d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b6a161e88d5, replyNumber=0, likeNumber=71, createdTime=2019-03-08, rootId=0, userName=446798725_87912766, userId=55065029738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b6a161e88d5, moduleTitle=OSE Immunotherapeutics的免疫检查点抑制剂： SIRPα单抗BI 765063获批在晚期实体瘤患者中进行1期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b6a161e88d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1443139, encodeId=a82e144313903, content=<a href='/topic/show?id=feee598219f' target=_blank style='color:#2F92EE;'>#晚期实体瘤#</a>, objectTitle=Alkermes开始验证ALKS 4230治疗晚期实体瘤的有效性, objectType=article, longId=161430, objectId=98231614302a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=98231614302a, replyNumber=0, likeNumber=64, createdTime=2019-03-02, rootId=0, userName=446798725_87912766, userId=55065029738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=98231614302a, moduleTitle=Alkermes开始验证ALKS 4230治疗晚期实体瘤的有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=98231614302a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1443138, encodeId=4d2c144313863, content=<a href='/topic/show?id=feee598219f' target=_blank style='color:#2F92EE;'>#晚期实体瘤#</a>, objectTitle=II期临床研究FUZE评估Debio 1347治疗晚期实体瘤的疗效, objectType=article, longId=160427, objectId=61c716042e5f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61c716042e5f, replyNumber=0, likeNumber=81, createdTime=2019-02-20, rootId=0, userName=446798725_87912766, userId=55065029738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61c716042e5f, moduleTitle=II期临床研究FUZE评估Debio 1347治疗晚期实体瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61c716042e5f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1443137, encodeId=dba9144313e45, content=<a href='/topic/show?id=feee598219f' target=_blank style='color:#2F92EE;'>#晚期实体瘤#</a>, objectTitle=Wnt口服抑制剂RXC004重新开始I / IIa期试验治疗晚期实体瘤, objectType=article, longId=158884, objectId=c80615888470, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c80615888470, replyNumber=0, likeNumber=76, createdTime=2019-01-27, rootId=0, userName=446798725_87912766, userId=55065029738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c80615888470, moduleTitle=Wnt口服抑制剂RXC004重新开始I / IIa期试验治疗晚期实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c80615888470)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1443136, encodeId=6cc2144313690, content=<a href='/topic/show?id=feee598219f' target=_blank style='color:#2F92EE;'>#晚期实体瘤#</a>, objectTitle=CLIN CANCER RES：ALT-803治疗晚期实体瘤患者, objectType=article, longId=154099, objectId=708c15409934, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=708c15409934, replyNumber=0, likeNumber=72, createdTime=2018-11-23, rootId=0, userName=446798725_87912766, userId=55065029738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=708c15409934, moduleTitle=CLIN CANCER RES：ALT-803治疗晚期实体瘤患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=708c15409934)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1443135, encodeId=b7901443135f3, content=<a href='/topic/show?id=feee598219f' target=_blank style='color:#2F92EE;'>#晚期实体瘤#</a>, objectTitle=JCO：Epacadostat 联合 Pembrolizumab治疗晚期实体瘤, objectType=article, longId=150031, objectId=8f8f1500318b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f8f1500318b, replyNumber=0, likeNumber=122, createdTime=2018-10-01, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f8f1500318b, moduleTitle=JCO：Epacadostat 联合 Pembrolizumab治疗晚期实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f8f1500318b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1443134, encodeId=c3101443134e5, content=<a href='/topic/show?id=feee598219f' target=_blank style='color:#2F92EE;'>#晚期实体瘤#</a>, objectTitle=AsiDNA 治疗晚期实体瘤的I期临床试验正式启动, objectType=article, longId=136480, objectId=e597136480eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e597136480eb, replyNumber=0, likeNumber=74, createdTime=2018-04-27, rootId=0, userName=446798725_87912766, userId=55065029738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e597136480eb, moduleTitle=AsiDNA 治疗晚期实体瘤的I期临床试验正式启动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e597136480eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1443133, encodeId=7474144313351, content=<a href='/topic/show?id=feee598219f' target=_blank style='color:#2F92EE;'>#晚期实体瘤#</a>, objectTitle=EUR J Cancer：用以晚期实体瘤患者治疗的选择性MET酪氨酸激酶抑制剂SAR125844的I期临床, objectType=article, longId=124748, objectId=f1cf124e4855, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1cf124e4855, replyNumber=0, likeNumber=0, createdTime=2017-12-28, rootId=0, userName=446798725_87912766, userId=55065029738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1cf124e4855, moduleTitle=EUR J Cancer：用以晚期实体瘤患者治疗的选择性MET酪氨酸激酶抑制剂SAR125844的I期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1cf124e4855)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1443132, encodeId=fe6314431329e, content=<a href='/topic/show?id=feee598219f' target=_blank style='color:#2F92EE;'>#晚期实体瘤#</a>, objectTitle=CLIN CANCER RES：抗肿瘤干细胞药物Ipafricept治疗晚期实体瘤患者, objectType=article, longId=123740, objectId=e667123e40a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e667123e40a4, replyNumber=0, likeNumber=82, createdTime=2017-12-19, rootId=0, userName=446798725_87912766, userId=55065029738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e667123e40a4, moduleTitle=CLIN CANCER RES：抗肿瘤干细胞药物Ipafricept治疗晚期实体瘤患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e667123e40a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1443131, encodeId=4eb014431316b, content=<a href='/topic/show?id=feee598219f' target=_blank style='color:#2F92EE;'>#晚期实体瘤#</a>, objectTitle=Oncotarget：Elenagen疫苗在晚期实体瘤治疗中表现安全性和抗肿瘤活性，并能恢复肿瘤对化学疗法的敏感性, objectType=article, longId=100552, objectId=168c1005523e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=168c1005523e, replyNumber=0, likeNumber=103, createdTime=2017-06-04, rootId=0, userName=446798725_87912766, userId=55065029738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=168c1005523e, moduleTitle=Oncotarget：Elenagen疫苗在晚期实体瘤治疗中表现安全性和抗肿瘤活性，并能恢复肿瘤对化学疗法的敏感性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=168c1005523e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1443130, encodeId=503c144313060, content=<a href='/topic/show?id=feee598219f' target=_blank style='color:#2F92EE;'>#晚期实体瘤#</a>, objectTitle=The Lancet Oncology：Avelumab用于转移性或局部晚期实体瘤, objectType=article, longId=94245, objectId=80ff942459a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80ff942459a, replyNumber=0, likeNumber=106, createdTime=2017-04-02, rootId=0, userName=446798725_87912766, userId=55065029738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80ff942459a, moduleTitle=The Lancet Oncology：Avelumab用于转移性或局部晚期实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=80ff942459a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1443129, encodeId=b44214431290c, content=<a href='/topic/show?id=feee598219f' target=_blank style='color:#2F92EE;'>#晚期实体瘤#</a>, objectTitle=Clin Cancer Res：人体首例第二代非安莎霉素HSP90抑制剂（AT13387）治疗晚期实体瘤的一期临床试验, objectType=article, longId=41678, objectId=4031416e864, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4031416e864, replyNumber=0, likeNumber=77, createdTime=2014-10-25, rootId=0, userName=446798725_87912766, userId=55065029738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4031416e864, moduleTitle=Clin Cancer Res：人体首例第二代非安莎霉素HSP90抑制剂（AT13387）治疗晚期实体瘤的一期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4031416e864)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

晚期实体瘤

2020-05-29

446798725_87912766

#晚期实体瘤#

如何治疗间皮素阳性晚期实体瘤？新型T细胞疗法TC-210有效性显著

2020-07-29

446798725_87912766

#晚期实体瘤#

ATG-008联合特瑞普利单抗完成首例晚期实体瘤和HCC患者给药

2020-05-03

446798725_87912766

#晚期实体瘤#

AACR 2020：索凡替尼联合特瑞普利单抗治疗晚期实体瘤Ⅰ期研究结果公布

2020-05-03

446798725_87912766

#晚期实体瘤#

Lancet Oncol：Larotrectinib治疗TRK融合阳性晚期实体瘤

2020-03-03

446798725_87912766

#晚期实体瘤#

Hyleukin-7（NT-I7）联合Pembrolizumab治疗复发难治晚期实体瘤：美国FDA已批准IND申请

2020-01-30

zhouqu_8

#晚期实体瘤#

加拿大卫生部批准VITRAKVI®（larotrectinib）治疗NTRK基因融合的晚期实体瘤

2019-08-01

446798725_87912766

#晚期实体瘤#

ASCO2019 |新型融合抗PD-L1抗体试用在中国晚期实体瘤患者中的应用

2019-06-04

446798725_87912766

#晚期实体瘤#

SYNB1891与PD-L1检查点抑制剂联合治疗晚期实体瘤

2019-05-25

446798725_87912766

#晚期实体瘤#

OSE Immunotherapeutics的免疫检查点抑制剂： SIRPα单抗BI 765063获批在晚期实体瘤患者中进行1期临床研究

2019-03-08

446798725_87912766

#晚期实体瘤#

Alkermes开始验证ALKS 4230治疗晚期实体瘤的有效性

2019-03-02

446798725_87912766

#晚期实体瘤#

II期临床研究FUZE评估Debio 1347治疗晚期实体瘤的疗效

2019-02-20

446798725_87912766

#晚期实体瘤#

Wnt口服抑制剂RXC004重新开始I / IIa期试验治疗晚期实体瘤

2019-01-27

446798725_87912766

#晚期实体瘤#

CLIN CANCER RES：ALT-803治疗晚期实体瘤患者

2018-11-23

zhaojie88

#晚期实体瘤#

JCO：Epacadostat 联合 Pembrolizumab治疗晚期实体瘤

2018-10-01

446798725_87912766

#晚期实体瘤#

AsiDNA 治疗晚期实体瘤的I期临床试验正式启动

2018-04-27

446798725_87912766

#晚期实体瘤#

EUR J Cancer：用以晚期实体瘤患者治疗的选择性MET酪氨酸激酶抑制剂SAR125844的I期临床

2017-12-28

446798725_87912766

#晚期实体瘤#

CLIN CANCER RES：抗肿瘤干细胞药物Ipafricept治疗晚期实体瘤患者

2017-12-19

446798725_87912766

#晚期实体瘤#

Oncotarget：Elenagen疫苗在晚期实体瘤治疗中表现安全性和抗肿瘤活性，并能恢复肿瘤对化学疗法的敏感性

2017-06-04

446798725_87912766

#晚期实体瘤#

The Lancet Oncology：Avelumab用于转移性或局部晚期实体瘤

2017-04-02

446798725_87912766

#晚期实体瘤#

Clin Cancer Res：人体首例第二代非安莎霉素HSP90抑制剂（AT13387）治疗晚期实体瘤的一期临床试验

2014-10-25

科室
- - 订阅+
  - 更多科室
工具
服务